The NeurologyLive® NMOSD Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with neuromyelitis optica spectrum disorder.
Whole Brain Volume Loss, Higher Thalamic and Hippocampal Atrophy Rate Identified in MOGAD
A cross-sectional and longitudinal comparative analysis suggests a subclinical neurodegenerative process may occur in MOG antibody disease based on a distinct pattern of brain atrophy.
Relapse Patterns and Disease Phenotype Correlate With Treatment Change in NMOSD
Results from the CIRCLES cohort demonstrated a significant association in relapse patterns and disease phenotype for patients with NMOSD who change treatment.
NeurologyLive® Brain Games: January 29, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromyelitis optica spectrum disorder, or NMOSD.
International Panel of Experts Proposes New Diagnostic Criteria for MOG Antibody Associated Disease
The new criteria, inclusive of both pediatric and adult patients, advocates for testing for MOG-IgG in appropriate populations, and cautions against testing patients with clinical and radiological features typical of multiple sclerosis.
Argentinean-Based Study Highlights International Barriers to Access and Utilization of NMOSD Care
Data showed that slightly more than half of the patients with NMOSD visited at least 2 neurologists before receiving full diagnosis, and less than 30% reported they were aware of at least 1 nearby specialized NMOSD center.
Older Patients With Onset NMOSD Experience More Frequent Transverse Myelitis
According to a medical records analysis, patients with late onset NMOSD experience transverse myelitis more frequently at disease onset in comparison with early onset NMOSD.
Research Highlights Trends and Impacts of Comorbidities in NMOSD
Featuring a cohort of more than 500 patients with NMOSD, data showed that those with comorbidities exhibit multiple presentations and are more likely to relapse after immunotherapy.
CT103A Displays Manageable Safety Profile in Relapsed, Refractory AQP4-IgG Seropositive NMOSD
Results from on ongoing phase 1 trial showed a favorable safety profile with CT103A in patients with NMOSD.
Rare, Fatal Case of Neuromyelitis Optica Post–COVID-19 Vaccination Explained
A rare case of neuromyelitis optica was reported with a woman aged in her 70s from Iran who experienced neurological symptoms after COVID-19 vaccination.
Rare Seronegative NMOSD Case Identified
A study reported a rare case of seronegative NMOSD with a middle-aged man in Nepal who did not improve in clinical status and performance after given treatment.
Case Report Highlights Diagnosis of Antibody-Positive NMOSD After Second COVID-19 Vaccination
A rare case report illustrated an 80-year-old man with aquaporin-4 antibody-positive NMOSD following a second dose of the Pfizer-BioNTech COVID-19 mRNA BNT162b2 vaccine.
Visual Field Defect Higher in Patients with NMOSD-ON Than Idiopathic ON
Results from a prospective study demonstrated a higher visual field defect in patients with neuromyelitis optica spectrum disorder-optic neuritis compared with those who had idiopathic optic neuritis.
Building the Biomarker Panel in Neurology: Glial Fibrillary Acidic Protein
As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.
Treating NMOSD Early in the Disease Course: Inebilizumab’s Efficacy in N-MOmentum
Bruce Cree, MD, PhD, MAS, FAAN, offered his perspective on data from the phase 2/3 N-MOmentum trial of the recently approved inebilizumab (Uplizna; Horizon Therapeutics) and why the therapy stands out from other NMOSD treatments.
Suitable Dosage of Rituximab for NMOSD Associated With Lower Risk of Adverse Events
A meta-analysis suggests that 100mg/w rituximab for 3 consecutive weeks may be the appropriate dosage for patients of NMOSD, demonstrated by a low risk of adverse events.
The Sumaira Foundation Providing Access to Care for Patients with NMOSD: Sumaira Ahmed
The founder and executive director of the Sumaira Foundation discussed her experience living with NMOSD and the global organization she created to help patients with the same condition. [WATCH TIME: 6 minutes]
Occurrence of Late-Onset Neurotropenia After Anti-CD20 Therapy: Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCI
The senior consultant for the department of neurology at the National Neuroscience Institute discussed a report on two patients who developed an uncommon adverse event of late-onset neurotropenia after anti-CD20 therapy treatment. [WATCH TIME: 8 minutes]
NeuroVoices: Bruce Cree, MD, PhD, MAS, FAAN, on the Importance of Biomarker Studies in NMO and Role of NfL, GFAP
The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on several analyses from the N-MOmentum trial that highlight the clinical use of biomarkers in NMO and NMOSD.
Role of Serum Neurofilament Light in Predicting Neuromyelitis Optica Attacks: Bruce Cree, MD, PhD, MAS, FAAN
The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on the importance of serum neurofilament light and how it can be used in the management of patients with NMOSD. [WATCH TIME: 3 minutes]
Critical Aspects of Treatment During Postpartum in Patients with MS, NMOSD: Riley Bove, MD
The associate professor of neurology at the University of California, San Francisco, discussed the key points from an oral presentation at ECTRIMS 2022 on understanding postpartum for patients with MS and NMOSD. [WATCH TIME: 4 minutes]
Emerging Biomarkers to Consider for NMOSD, Neuromyeltis Optica: Bruce Cree, MD, PhD, MAS, FAAN
The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]
Positive Safety Profile of Anti-CD20 Therapy During Postpartum in MS, NMOSD: Riley Bove, MD
The associate professor of neurology at the University of California, San Francisco, discussed takeaways from an oral presentation at ECTRIMS 2022 on the use of anti-CD20 therapies in postpartum for patients with MS and NMOSD. [WATCH TIME: 5 minutes]
Inebilizumab’s Impact on B-Cells, Plasmablasts, and Plasma Cells in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
The clinical research director of the UCSF Multiple Sclerosis Center provided insight on an abstract from ECTRIMS 2022 regarding inebilizumab’s mechanism of action to prevent NMOSD attacks. [WATCH TIME: 3 minutes]
Specific Risk Factors Related to Permanent Disability in NMOSD Identified
Permanent disability, found in 51% of patients with NMOSD at follow-up, was attributed mainly to age of disease onset, delay in diagnosis, and initial EDSS score.
Similar Retinal Measurements Observed in Potential NMOSD and Definite NMOSD
A cross-sectional study showed that retinal measurements in patients with “potential” neuromyelitis optica spectrum disorder were similar to those with definite neuromyelitis optica spectrum disorder.
Anti-CD20 Therapies in Late-onset Neutropenia Result in an Uncommon Adverse Event
A report on two patients with late-onset neutropenia resulted in an uncommon adverse event following anti-CD20 therapies.
Greater Abnormal Visual Evoked Potential Found in NMOSD Than Idiopathic Demyelinating Optic Neuritis
P100 amplitude of 15 minute checks in the NMOSD-ON group had a significant reduction at 6 months relative to the IDON group, suggesting more several axonal damage.
Early Use of Immunosuppressives May Reduce Pregnancy-Related NMOSD Attacks
Annualized relapse rates were elevated compared with the prepregnancy period, especially during the initial 3 months after delivery, whereas EDSS scores worsened during pregnancy and the postpartum period.
Rituximab Treatment Associated with Reduced Relapse Rate in AQP4-IgG Positive NMOSD and MOGAD
A study using patient data from John Hopkins showed that rituximab treatment was associated with reduced annualized relapse rates in AQP4-IgG seropositive NMOSD and MOGAD.
Total N-Acetylaspartate Different Across Antibody-Negative Overlapping Multiple Sclerosis, NMOSD
Using magnetic resonance spectroscopy, investigators observed significantly different levels of total NAA across MS and NMOSD subtypes, and a negative correlation between total NAA and disability score.
Blocking B Cells may be the Key to Controlling NMOSD Over Time
Rituximab Displays Superiority to Azathioprine, Mycophenolate Mofetil as Initial NMOSD Treatment
Among a cohort of more than 300 patients in China, those with APQ4 positive NMOSD reported a significantly lower risk of relapse among those treated with rituximab compared with the other groups.
The Patient Perspective on Neuromyelitis Optica Spectrum Disorder: Sumaira Ahmed
The founder and executive director of the Sumaira Foundation offered her perspective on the patient journey in NMOSD and the vital need to increase awareness [WATCH TIME: 9 minutes]
Abnormal Activation of BTK/NF-kB Identified in Acute, Remitted Cases of NMOSD
CXCL2 and CXCL12, known to induce B-cell proliferation and differentiation, were significantly higher in those with acute and remitted cases of NMOSD compared with controls.
Germinal Center Activity Shows Potential As Target of Rituximab in NMOSD
Data assessing samples of deep cervical lymph node aspirates and blood suggest that germinal center activity was associated with clinical relapses in individuals with neuromyelitis optica spectrum disorder.
Long-term Immunosuppression Treatment Is Suitable for Patients With NMOSD
Data suggest that long-term treatment with immunosuppression therapies, such as rituximab, is generally appropriate for patients with neuromyelitis optica, though transverse myelitis might indicate a higher risk of relapse post discontinuation.
Characteristics of Bilateral Parafalcine Cortical Leptomeningeal Impairment in NMOSD, MOGAD Identified to Avoid Misdiagnosis
BPCLI was observed in both NMOSD and MOGAD but was relatively rarer in AQP4 NMOSD, with meningoencephalitis-like episodes among the sources of misdiagnosis.
NeurologyLive® Brain Games: August 7, 2022
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromyelitis optica spectrum disorder.
Greater Link Identified in NMOSD Between Time-Varying Functional Connectivity and Depressive Symptoms Than Static Connectivity
In a cohort of patients with NMOSD, more severe depressive symptoms were associated with increased time-varying functional connectivity between the precuneus and temporal cortex.
Cerebrospinal GFAP Levels in Double-Seronegative NMOSD Indicate Different Pathology
Using rigorous cell-based assays, cerebrospinal fluid GFAP levels were significantly lower in double-seronegative NMOSD than AQP4-positive NMOSD but did not differ between those with MOGAD or other neurological diseases.
Technological Advancements Improving, Expanding Capabilities of Antibody Testing: Sean Pittock, MD
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the technological capabilities the center has, including the improved use of neural antibody testing. [WATCH TIME: 6 minutes]
Link Observed Between Neuropathic Pain and Constipation in NMOSD, MOGAD
Neuropathic pain and constipation coexisted in 43.5% of the survey participants, and approximately one-third of patients with both symptoms reported a possible link between the two.
Cognitive Impairments, Visual Memory Hindered in Neuromyelitis Optica Spectrum Disorder
Between AQP4-IgG-positive and negative patients with NMOSD, there were no significant differences in cognitive performance, despite having similar demographic and clinical characteristics.
Presence of MOG-IgG in Children Meeting MS Criteria May Allude to Nontypical Disease Course
All 12 of the children met diagnostic criteria for multiple sclerosis and were seropositive for MOG-IgG at baseline experienced a disease course different than typical MS through the observed time.
Distinguishing and Diagnosing Various Presentations of Autoimmune Encephalitis: Sean Pittock, MD
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the complexities in diagnosing autoimmune encephalitis and the approach needed to be taken. [WATCH TIME: 5 minutes]
Pioneering Care for Autoimmune Disorders Through Research and Results: The Mayo Clinic Way
Through dedicated research into biomarker discovery and patient care, the neuroimmunology laboratory at Mayo Clinic has paved a new way of life for those with autoimmune disorders.
Inebilizumab Reduces Severity of Attacks in Patients With NMOSD
Findings from a new post hoc analysis of data from the randomized-controlled period of the N-MOmentum phase 2/3 pivotal trial (NCT02200770), suggest the Horizon agent is effective in NMOSD.
Managing and Treating Neuromyelitis Optica Spectrum Disorder
An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.
Brighter Spotty Lesions Show Potential in Distinguishing AQP4-NMOSD From MOGAD
These findings have clinical implications for the diagnosis of AQP4-NMOSD and in helping clinicians differentiating it from other demyelinating diseases such as MOGAD.
Outlining the Clinical and Radiological Features of NMOSD, MOGAD
Amy Kunchok, MD, staff neurologist at the Mellen Center for Multiple Sclerosis and Research at Cleveland Clinic, discussed a recent talk she gave that highlighted the different phenotypes of AQP-IgG NMOSD and MOGAD.
Clinical, Radiological Features of NMOSD and MOGAD: Amy Kunchok, MD
The staff neurologist at the Cleveland Clinic Mellen Center for Multiple Sclerosis outlined key findings from her talk at a recent Institutional Perspectives in Neurology: Multiple Sclerosis event. [WATCH TIME: 3 minutes]
New Remission Lesions Rare, May Indicate Relapse in MOGAD, AQP4-NMOSD
Results from the cohort study contrast with reports in multiple sclerosis, finding that new remission silent lesions were rare in both myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder.
B-Cell Depletion and Long-Term Outcomes in NMOSD With Inebilizumab: Jeffrey Bennett, MD, PhD
The professor of neurology at the University of Colorado provided insight on the data that reinforced the relationship between B-cell depletion and improved outcomes using inebilizumab (Uplizna; Horizon Therapeutics). [WATCH TIME: 2 minutes]
Inebilizumab Efficacy Unchanged With Prior Rituximab Use in NMOSD
Annualized attack rate was reduced to 0.08 attacks per year after the first administration of inebilizumab, similar to those who were not previously exposed to rituximab.
Outer Retinal Layer Thinning Non-Factor in Retinal Damage of AQP4-IgG NMOSD
Repeated analyses using both 3-mm and 1-mm diameter macular data—narrower volumes than standard—showed no relevant outer plexiform layer or outer nuclear layer thinning in those with seropositive AQP4-IgG.
Priorities in NMO: Biomarkers, Therapy Discontinuation, and More With Marcelo Matiello, MD
The associate director of the Neuromyelitis Optica Clinic and Research Unit at Mass General spoke about some of the unmet needs and unanswered questions surrounding NMO management.
Better COVID-19 Outcomes in MOGAD Than NMOSD, Registry Data Show
Data presented at CMSC 2021 suggest worse COVID-19 outcomes were associated with patients with neuromyelitis optica spectrum disorder and other comorbidities.
Satralizumab Demonstrates Long-Term Safety in NMOSD
Rates of infection or serious infection with satralizumab in the overall treatment period were not higher than those on placebo in the double-blind period and did not increase over time.
New Sponsors, Potential Development in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]
Understanding the Value of B-Cell Depletion in NMOSD
Jeffrey Bennett, MD, PhD, professor of neurology, University of Colorado, discussed his presentation at ECTRIMS involving the relationship of B-cell depletion and improved outcomes in patients treated with inebilizumab.
Eculizumab Shows Better Prolonging of Time to NMOSD Relapse Than Other Treatments
An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.
Patient Education and Awareness in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
The clinical research director of the USCF Multiple Sclerosis Center discussed the importance of improving knowledge and education for patients with NMOSD, as well as strategies to do so. [WATCH TIME: 3 minutes]
Day-to-Day Care of NMOSD, Advances and Challenges: Bruce Cree, MD, PhD, MAS, FAAN
Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]
Understanding Disadvantages to African Americans in NMOSD Trials: Evanthia Bernitsas, MD
The neurologist at Wayne State University provided background on why there needs to be a continued focus on including and studying African American patients with NMOSD in trials. [WATCH TIME 3 minutes]
Treating NMOSD: What to Expect
Neuromyelitis optica patient Doug highlights the types of treatments he has received since his diagnosis and provides suggestions to patients on navigating therapy, especially during the COVID-19 pandemic.
Navigating NMOSD Infusion-Based Treatment
Kim, a patient with neuromyelitis optica, describes what it has been like receiving rituximab infusions as preventive therapy, and shares advice for others who are about to embark on a similar treatment journey.
Recent Advances and New Therapies for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
The clinical research director of the UCSF Multiple Sclerosis Center provided an overview on the state of care for NMOSD, specifically the development of inebilizumab, satralizumab, and eculizumab. [WATCH TIME: 6 minutes]
Onset Presentation Predicts First Relapse, Long-Term Disability in Pediatric AQP4-IgG NMOSD
Investigators suggest recognition of predictors can aid in directing future clinical trials, as well as inform early therapeutic decisions in this patient population.
Inebilizumab’s Safe and Effective Profile for African Americans With NMOSD
Evanthia Bernitsas, MD, neurologist, Wayne State University, discussed a recently conducted analysis, which confirmed inebilizumab’s ability to treat African Americans with NMOSD.
Inebilizumab Demonstrates Long-Term Efficacy, Safety in AQP4-Positive NMOSD
Most attacks occurred within the first year of inebilizumab treatment, and nearly all participants were attack free in subsequent years following treatment initiation.
Inebilizumab’s Efficacy in African Americans With NMOSD: Evanthia Bernitsas, MD
The neurologist at Wayne State University School of Medicine discussed recently published data describing inebilizumab’s role in producing rapid and sustained B-cell depletion in African Americans with NMOSD [WATCH TIME: 4 minutes]
Treating NMOSD During COVID-19
What to know about treating patients with neuromyelitis optica spectrum disorders throughout the COVID-19 pandemic.
NMOSD Acute Attack Prevention
An overview of newer preventive therapies approved for acute attacks of neuromyelitis optica spectrum disorders, and variables that impact treatment selection.
Survey Identifies New Phenotypic Features for Patients With NMOSD in Latin America
The study is the first to provide data from all Latin American countries, further identifying geographic-resultant limitations of access to technology and therapy for NMOSD.
Identifying and Managing NMOSD
Types of testing that can help neurologists distinguish between acute attacks of neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis, as well as therapies that can be used to help manage patients with NMOSD.
The Guthy-Jackson Charitable Foundation for NMOSD
Jacinta M. Behne, MA, describes how the Guthy-Jackson Charitable Foundation supports patients with neuromyelitis optica spectrum disorders.
Eculizumab Provides Long-Term Effective Management of NMOSD
Between PREVENT baseline and end, mean EDSS and Hauser Ambulation Index scores improved with eculizumab (Soliris; Alexion) monotherapy and deteriorated with placebo alone.
NMOSD Attack Characteristics and Outcomes Classified by Phenotype, Treatment Option
The findings identified Th2-related cytokines as characterizing for the prognosis of acute episodes of NMOSD at 1 month and found serum NfL to be a likely biomarker of disease severity at attack.
NMOSD Relapse Risk Prevalent After Discontinuation of Immunosuppressive Therapy
More than 80% of those with NMOSD experienced disease relapse 6 months after discontinuation of immunosuppressive therapy.
Receiving a Diagnosis of NMOSD
Doug and Kim, patients with neuromyelitis optica spectrum disorders, describe the types of symptoms that prompted each of them to seek an evaluation by a neurologist for an eventual diagnosis of a neuromyelitis optica spectrum disorder.
Raising Awareness About NMOSD
Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.
Neuro-News Roundup: NMOSD – Latest Literature and Expert Conversations
Get the latest news in neuromyelitis optica spectrum disorder, with data updates and expert insights, all in one place from the NeurologyLive team.
First Patients Enrolled in SPHERES Registry for Neuromyelitis Optica Spectrum Disorder
The registry aims to enroll approximately 800 patients with NMOSD to evaluate the efficacy of new medications and treatments.
NeuroVoices: Sean Pittock, MD, on Improving Treatment Optimization, Clinical Pipeline of NMOSD
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed unmet needs of care for patients with neuromyelitis optica spectrum disorder.
Addressing the Current State of Care, Pipeline in NMOSD: Melanie Truong-Le, DO, OD
The neuro-ophthalmologist at UT Southwestern further discussed the high cost of treatment for patients with neuromyelitis optica spectrum disorder and the need to improve access to care.
Optic Neuritis and NMOSD Diagnosis: Melanie Truong-Le, DO, OD
The neuro-ophthalmologist at UT Southwestern Medical Center discussed optical coherence tomography and antibody detection technology used to diagnose optic neuritis associated with NMOSD.
Assessing the State of NMOSD Treatment Following Treatment Influx
The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided context on challenges within the NMOSD space and what’s next following the first-approved therapies.
Recent Advancements in NMOSD Clinical Care: Melanie Truong-Le, DO, OD
Discussing NMOSD’s relation to AQP4 and pattern enhancement on MRIs, the neuro-ophthalmologist at UT Southwestern Medical Center further commented on the importance of early diagnosis.
The Status of NMOSD Patient Education and the Development Pipeline
Bruce Cree, MD, PhD, clinical research director of the UCSF Multiple Sclerosis Center, provided context on the status of patient education efforts and clinical development for neuromyelitis optica spectrum disorder.
Melanie Truong-Le, DO, OD, on the State of NMOSD and Optic Neuritis
The neuro-ophthalmologist from UT Southwestern Medical Center provided her opinion on the state of care for patients with NMOSD and associated optic neuritis technology.
Greatest Strides Made in NMOSD Care: Sean Pittock, MD
The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the most notable recent advances that has propelled care for patients with NMOSD.
Bruce Cree, MD, PhD, on the Historically Fast Progress Made in NMOSD Care
The clinical research director of the UCSF Multiple Sclerosis Center shared his perspective on the history of clinical care for neuromyelitis optica spectrum disorder in light of 3 recent FDA approvals.
MOG-Ab Screening May Facilitate Diagnosis and Treatment of NMOSD
Investigators found that frequency of MOG-Ab associated NMOSD was not significantly different between Asian and Caucasian populations despite the prevalence of NMOSD in Asian regions.
Distinct MRI Features Identified Between AQP4-NMOSD and MOG-Antibody Disease
Lesions in the canalicular and intracranial optic nerve, area postrema, medulla, and cervical spinal cord were prominent in patients with aquaporin-4–NMOSD.
Critical Aspects of NMOSD Clinical Care: Brian G. Weinshenker, MD
The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.
Promising Biomarkers for NMOSD Activity: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed which biomarkers have shown the most relevancy in NMOSD and which deserve more attention.
Future Directions of NMOSD Research: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed several areas within the neuromyelitis optica spectrum disorder that are of interest for ongoing and new research efforts.
Longitudinal Brain Atrophy Present in Clinically Inactive NMOSD, MS
Patients with AQP4+NMOSD with long cord lesion showed higher annualized atrophy rate of normalized grey matter volume compared with those without long cord lesion.
NMOSD Treatment Landscape and Pipeline: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed the 3 currently FDA-approved agents for NMOSD and other agents currently within the clinical pipeline.
Unsolved Questions Regarding NMOSD Disease Progression: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed lesser-known facets of NMOSD and how the disease evolves over time.
Biggest Advances in NMOSD Management, Diagnosis: Brian G. Weinshenker, MD
The professor of neurology at the Mayo Clinic College of Medicine detailed the strides made in recognizing NMOSD as its own disease, along with specific biomarkers that identify it.
Anti-CD20 Therapy for MS and NMOSD Linked to Lower COVID-19 Antibody Response
Among independent variables including DMT group, time from COVID-19 infection, total IgG level, age, sex, obesity, and COVID-19 severity, only the anti-CD20 group was associated with decreased odds of positive serology.
Temporal Evolution of MRI Lesions Identified in Different CNS Demyelinating Disorders
Complete resolution of the index T2-lesion and resolution of all T2 lesions occurred most often in patients with MOGAD rather than AQP4-IgG-NMOSD or MS.
Prevalence of MS and NMOSD in Indigenous Populations Dependent on Ancestry
Investigators evaluated the occurrence of multiple sclerosis and neuromyelitis optica spectrum disorder in Australian and New Zealand Indigenous populations, comparing data with ancestral data.
Identifying Atypical Forms, Presentations of Demyelinating Disease: Oliver Tobin, MBBCh, BAO, PhD
The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.
NMOSD Relapse Rates Lower During First Postpartum Trimester
These study results highlight the interest in immunosuppressive therapy taken before or during pregnancy and to reduce the risk of relapse during pregnancy and 1 year postpartum.
GFAP Represents Greatest Longitudinal Clinical Value Biomarker for NMOSD
Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.
Subcutaneous Satralizumab Gains EU Approval to Treat NMOSD
The basis for the approval was data from the phase 3 SAkuraSky and SAkuraStar studies, which combined included more than 170 patients who were treated with either satralizumab or placebo.
Quell TENS Device to be Used in NMOSD Study
NeuroMetrix will be evaluating the effectiveness of the transcutaneous electrical nerve stimulation platform in pain relief for patients with neuromyelitis optica spectrum disorder.
Optical Coherence Tomography Angiography Helps Differentiate MS and NMOSD
Although existing research has shown structural differences between multiple sclerosis and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.
Leaving a Nebulous State of Care for Patients With NMOSD: Bruce Cree, MD, PhD
The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.
Interleukin-6 Receptors in the Treatment of Neuromyelitis Optica Spectrum Disorder
NMOSD is associated with elevated levels of the pleiotropic cytokine interleukin-6, making the cytokine an apt therapeutic target.
The Long-Term Efficacy of Inebilizumab in NMOSD: Bruce Cree, MD, PhD, MAS
The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.
Inebilizumab Has Enduring Effect as NMOSD Treatment
Patients in the randomized controlled trial and the open-label extension treated with inebilizumab experienced similar rates of being attack-free, extending as far as 4 years.
Eculizumab Demonstrates Safety, No Increased Infection Rates in NMOSD or Myasthenia Gravis
The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.
2 Clarke Drive Cranbury, NJ 08512